Samsung Bioepis Secures 10-Year Exclusive Supply Deal in Brazil's $170 Million Rare Disease Drug Market
Samsung Bioepis will exclusively supply its biosimilar to Brazil's rare disease drug market, estimated at approximately $170 million, or 250 billion won, annually, for a period of 10 years.Samsung Bioepis announced on Oct. 20 that it had signed a local partnership agreement with Brazil's Ministry of
Samsung Bioepis has secured a 10-year exclusive supply deal in Brazil's $170 million rare disease drug market. The biosimilar, SB12, a copy of Soliris, will be exclusively supplied to the Brazilian government-led market starting in 2027. Samsung Bioepis will partner with Brazil's Ministry of Health and local companies Bionovis and Bahiafarma to transfer manufacturing technology.
SB12, a treatment for rare diseases like PNH and aHUS, received approval from Brazil's ANVISA in December 2025. Brazil's eculizumab market was valued at around $170 million in 2025. This marks Samsung Bioepis' third PDP agreement with the Brazilian government, expanding their portfolio to include SB12.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
